Ultragenyx Pharmaceutical Inc. (RARE) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

15/25

Growth 4 Margin 2 Expansion 4 Platform 2 Financial 3

latest quarter score

Earnings Reports

15
Ultragenyx (RARE) Q2 2026: Gene Therapy Launches Target 6,000-Patient Population, Setting Up 2027 Profitability Path
August 05, 2026
15
Ultragenyx (RARE) Q1 2026: 64% Ex-U.S. FKESA Growth Signals Pipeline-Driven Revenue Inflection
June 17, 2026
17
Ultragenyx (RARE) Q2 2025: Pipeline Drives 20% Revenue Growth as Phase III Programs Reach Inflection
June 16, 2026
16
Ultragenyx (RARE) Q3 2025: $400M Royalty Monetization Extends Runway Ahead of Transformative Readouts
June 16, 2026
13
RARE (Ultragenyx) Q4 2025: 20% Revenue Growth Amid Strategic Restructuring and Multiple Near-Term Catalysts
February 12, 2026
16
Ultragenyx (RARE) Q1 2025: Latin America Drives 52% CRISVITA Growth, Unlocking Global Rare Disease Upside
July 07, 2025

Browse all companies